Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine.

Advani G, Lim YC, Catimel B, Lio DSS, Ng NLY, Chüeh AC, Tran M, Anasir MI, Verkade H, Zhu HJ, Turk BE, Smithgall TE, Ang CS, Griffin M, Cheng HC.

Cell Commun Signal. 2017 Aug 7;15(1):29. doi: 10.1186/s12964-017-0186-x.

2.

Sirt1 negatively regulates FcεRI-mediated mast cell activation through AMPK- and PTP1B-dependent processes.

Li X, Lee YJ, Jin F, Park YN, Deng Y, Kang Y, Yang JH, Chang JH, Kim DY, Kim JA, Chang YC, Ko HJ, Kim CH, Murakami M, Chang HW.

Sci Rep. 2017 Jul 25;7(1):6444. doi: 10.1038/s41598-017-06835-3.

3.

Effects of Src Kinase Inhibition on Expression of Protein Tyrosine Phosphatase 1B after Brain Hypoxia in a Piglet Animal Model.

Angelis D, Delivoria-Papadopoulos M.

Mediators Inflamm. 2017;2017:2810295. doi: 10.1155/2017/2810295. Epub 2017 May 23.

4.

Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells.

Hilmarsdottir B, Briem E, Halldorsson S, Kricker J, Ingthorsson S, Gustafsdottir S, Mælandsmo GM, Magnusson MK, Gudjonsson T.

Cell Death Dis. 2017 May 11;8(5):e2769. doi: 10.1038/cddis.2017.177.

5.

Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.

Liao SC, Li JX, Yu L, Sun SR.

J Zhejiang Univ Sci B. 2017 Apr.;18(4):334-342. doi: 10.1631/jzus.B1600184.

6.

Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors.

Mei W, Wang K, Huang J, Zheng X.

PLoS One. 2016 Nov 17;11(11):e0166538. doi: 10.1371/journal.pone.0166538. eCollection 2016.

7.

MenaINV dysregulates cortactin phosphorylation to promote invadopodium maturation.

Weidmann MD, Surve CR, Eddy RJ, Chen X, Gertler FB, Sharma VP, Condeelis JS.

Sci Rep. 2016 Nov 8;6:36142. doi: 10.1038/srep36142.

8.

Pancreatic Protein Tyrosine Phosphatase 1B Deficiency Exacerbates Acute Pancreatitis in Mice.

Bettaieb A, Koike S, Chahed S, Bachaalany S, Griffey S, Sastre J, Haj FG.

Am J Pathol. 2016 Aug;186(8):2043-2054. doi: 10.1016/j.ajpath.2016.04.012. Epub 2016 Jul 20.

9.

Simultaneous deactivation of FAK and Src improves the pathology of hypertrophic scar.

Su L, Li X, Wu X, Hui B, Han S, Gao J, Li Y, Shi J, Zhu H, Zhao B, Hu D.

Sci Rep. 2016 May 16;6:26023. doi: 10.1038/srep26023.

10.

A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation.

Song GJ, Jung M, Kim JH, Park H, Rahman MH, Zhang S, Zhang ZY, Park DH, Kook H, Lee IK, Suk K.

J Neuroinflammation. 2016 Apr 19;13(1):86. doi: 10.1186/s12974-016-0545-3.

11.

Prediction and verification of novel peptide targets of protein tyrosine phosphatase 1B.

Li X, Köhn M.

Bioorg Med Chem. 2016 Aug 1;24(15):3255-8. doi: 10.1016/j.bmc.2016.03.030. Epub 2016 Mar 17.

12.

Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.

Hoekstra E, Das AM, Swets M, Cao W, van der Woude CJ, Bruno MJ, Peppelenbosch MP, Kuppen PJ, Ten Hagen TL, Fuhler GM.

Oncotarget. 2016 Apr 19;7(16):21922-38. doi: 10.18632/oncotarget.7829.

13.

PTP1B triggers integrin-mediated repression of myosin activity and modulates cell contractility.

González Wusener AE, González Á, Nakamura F, Arregui CO.

Biol Open. 2015 Dec 23;5(1):32-44. doi: 10.1242/bio.015883.

14.

Development of Novel Triazolo-Thiadiazoles from Heterogeneous "Green" Catalysis as Protein Tyrosine Phosphatase 1B Inhibitors.

Baburajeev CP, Dhananjaya Mohan C, Ananda H, Rangappa S, Fuchs JE, Jagadish S, Sivaraman Siveen K, Chinnathambi A, Ali Alharbi S, Zayed ME, Zhang J, Li F, Sethi G, Girish KS, Bender A, Basappa, Rangappa KS.

Sci Rep. 2015 Sep 21;5:14195. doi: 10.1038/srep14195.

15.

The importance of Src signaling in sarcoma.

Chen Q, Zhou Z, Shan L, Zeng H, Hua Y, Cai Z.

Oncol Lett. 2015 Jul;10(1):17-22. Epub 2015 May 6.

16.

Orthovanadate-induced vasocontraction is mediated by the activation of Rho-kinase through Src-dependent transactivation of epidermal growth factor receptor.

Yayama K, Sasahara T, Ohba H, Funasaka A, Okamoto H.

Pharmacol Res Perspect. 2014 Apr;2(2):e00039. doi: 10.1002/prp2.39. Epub 2014 Apr 1.

17.

Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia.

Banerjee A, Wang HY, Borgmann-Winter KE, MacDonald ML, Kaprielian H, Stucky A, Kvasic J, Egbujo C, Ray R, Talbot K, Hemby SE, Siegel SJ, Arnold SE, Sleiman P, Chang X, Hakonarson H, Gur RE, Hahn CG.

Mol Psychiatry. 2015 Sep;20(9):1091-100. doi: 10.1038/mp.2014.115. Epub 2014 Oct 21.

18.

Missing-in-Metastasis regulates cell motility and invasion via PTPδ-mediated changes in SRC activity.

Chaudhary F, Lucito R, Tonks NK.

Biochem J. 2015 Jan 1;465(1):89-101. doi: 10.1042/BJ20140573.

19.

Protein tyrosine phosphatases as potential therapeutic targets.

He RJ, Yu ZH, Zhang RY, Zhang ZY.

Acta Pharmacol Sin. 2014 Oct;35(10):1227-46. doi: 10.1038/aps.2014.80. Epub 2014 Sep 15. Review.

20.

Disruption of protein-tyrosine phosphatase 1B expression in the pancreas affects β-cell function.

Liu S, Xi Y, Bettaieb A, Matsuo K, Matsuo I, Kulkarni RN, Haj FG.

Endocrinology. 2014 Sep;155(9):3329-38. doi: 10.1210/en.2013-2004. Epub 2014 Jun 23.

Supplemental Content

Support Center